Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | BCL2 | P10415 | 6/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.51 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743551 | 0.89 | HTR7 (0.63) | HTR7BCL2BCL2L1BAK1DRD3 | |
| SCHEMBL1743533 | 0.87 | HTR7 (0.66) | HTR7BCL2BCL2L1BAK1DRD3 | |
| SCHEMBL1958974 | 0.84 | BCL2 (0.58) | HTR7BCL2BCL2L1BAK1 | |
| SCHEMBL1742388 | 0.82 | BCL2 (0.65) | BCL2BCL2L1 | |
| SCHEMBL1960149 | 0.82 | BCL2 (0.58) | HTR7BCL2BCL2L1BAK1 | |
| SCHEMBL1959679 | 0.81 | HTR7 (0.58) | HTR7BCL2BCL2L1BAK1 | |
| SCHEMBL1955301 | 0.81 | BCL2 (0.62) | BCL2BCL2L1BAK1 | |
| SCHEMBL1741545 | 0.81 | HTR7 (0.55) | HTR7BCL2BCL2L1BAK1 | |
| SCHEMBL2826626 | 0.80 | BCL2 (0.60) | HTR7BCL2BCL2L1BAK1 | |
| SCHEMBL1957222 | 0.80 | BCL2 (0.53) | HTR7BCL2BCL2L1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |